Real-world study of rurioctocog alfa pegol and emicizumab in US clinical practice among patients with hemophilia A.

Bleed rates were similar for patients receiving prophylaxis with emicizumab or rurioctocog alfa pegol after switching from prophylaxis with another FVIII. However, wastage associated with dispensing inaccuracies was greater with emicizumab.